Altamira Therapeutics Ltd. (CYTOF)
OTCMKTS · Delayed Price · Currency is USD
0.0700
-0.0250 (-26.32%)
Mar 9, 2026, 11:22 AM EST

Altamira Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Mar '26 Dec '24 Dec '23 Jan '23 Dec '21 Dec '20 2019 - 2015
Market Capitalization
10162730
Upgrade
Market Cap Growth
-65.60%-72.84%-75.59%-78.93%-10.02%459.12%
Upgrade
Enterprise Value
115111830
Upgrade
Last Close Price
0.100.113.4897.00726.001048.00
Upgrade
PB Ratio
0.130.060.18-0.631.881.58
Upgrade
P/TBV Ratio
-0.190.45--3.46
Upgrade
Debt / Equity Ratio
0.190.060.02-0.760.040.03
Upgrade
Net Debt / Equity Ratio
0.19-0.10-0.08-0.76-0.03-0.64
Upgrade
Net Debt / EBITDA Ratio
----1.160.082.04
Upgrade
Net Debt / FCF Ratio
-0.180.100.05-0.750.032.22
Upgrade
Quick Ratio
0.091.160.780.060.343.74
Upgrade
Current Ratio
0.111.321.380.140.843.83
Upgrade
Return on Equity (ROE)
-108.79%-118.79%--764.37%-44.88%-71.91%
Upgrade
Return on Assets (ROA)
-45.75%-48.12%-51.58%-26.97%-16.70%-21.99%
Upgrade
Return on Capital Employed (ROCE)
-115.40%-91.50%-81.40%83.60%-37.30%-29.70%
Upgrade
Earnings Yield
-1041.11%-2250.19%-311.15%-489.87%-69.52%-30.99%
Upgrade
FCF Yield
-809.80%-1653.94%-925.68%-160.34%-55.73%-18.30%
Upgrade
Buyback Yield / Dilution
-351.86%-476.54%-978.83%-37.51%-120.26%-
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.